Organon Reports Boosted Growth In Biosimilars Portfolio Revenue
The Company Attributes The Growth To Increasing Demand And Local Tenders
In what has been described by some analysts as a “solid start” to 2024, Organon has reported a 46% increase in revenue from its biosimilars portfolio amid broader improvement.
